Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer subtype, and metastatic ccRCC (mRCC) carries a poor prognosis with 5-year survival rates below 15%. Identifying molecular signatures that can predict metastatic risk and guide treatment decisions remains a major unmet clinical need.
The competing endogenous RNA (ceRNA) hypothesis proposes that non-coding RNAs, particularly long non-coding RNAs (lncRNAs), act as molecular sponges that sequester microRNAs (miRNAs), thereby derepressing miRNA target messenger RNAs (mRNAs). Dysregulated ceRNA networks can fundamentally alter gene expression programs that drive tumor progression and metastasis.
This study constructed a ceRNA network specifically for mRCC using integrated multi-omics data, then applied machine learning to extract a prognostic gene signature from the network components capable of predicting patient outcomes and identifying high-risk individuals most likely to progress to metastatic disease.
The training cohort comprised 602 patients from the TCGA-KIRC dataset, the largest publicly available ccRCC genomic resource with matched lncRNA, miRNA, and mRNA expression profiles. The external validation cohort included 91 patients from the ICGC-RECA (International Cancer Genome Consortium Renal Cancer) dataset, providing an independent population for model testing.
The ceRNA network was constructed by integrating differential expression analysis with miRNA-target interaction databases and lncRNA-miRNA binding predictions. Network edges represent predicted regulatory relationships: lncRNAs sponge miRNAs, which in turn regulate mRNA targets, forming a three-layer regulatory graph.
The final ceRNA network comprised 18 lncRNAs, 75 miRNAs, and 128 mRNAs, representing hundreds of regulatory interactions. Machine learning was then applied to identify the subset of network nodes with the strongest and most consistent prognostic signal across the training cohort.
Machine learning analysis identified an 11-component signature comprising 2 lncRNAs (SNHG15, AF117829.1), 2 miRNAs (hsa-miR-130a-3p, hsa-miR-381-3p), and 7 mRNAs (BTBD11, INSR, HECW2, RFLNB, PTTG1, HMMR, RASD1). Each component was selected for its independent prognostic contribution and its connectivity within the ceRNA network.
SNHG15 is a well-documented oncogenic lncRNA in multiple cancers, and its presence in the signature is consistent with its known role in promoting tumor cell proliferation and metastasis by sponging tumor-suppressive miRNAs. PTTG1 encodes pituitary tumor-transforming gene 1, a securin protein associated with chromosomal instability and aggressive tumor behavior.
HMMR (hyaluronan-mediated motility receptor) and INSR (insulin receptor) represent mRNA components with established roles in cell migration and metabolic signaling respectively, both processes critical for metastatic spread. The signature's biological coherence across network components strengthens confidence in its mechanistic relevance.
On the ICGC-RECA external validation cohort, the 11-gene signature achieved an AUC of 81.5% and overall accuracy of 72%. These metrics indicate strong and clinically meaningful discriminative ability for distinguishing high-risk from low-risk mRCC patients in a completely independent patient population.
Patients in the high-risk group defined by the signature had significantly shorter overall survival compared to low-risk patients, with hazard ratios consistent across both the TCGA training set and the ICGC validation set. This consistency across geographically and demographically distinct cohorts supports the signature's generalizability.
Subgroup analyses confirmed that the signature maintained prognostic significance across different clinical stages, histological grades, and treatment backgrounds, suggesting it captures a fundamental biological property of metastatic ccRCC rather than a cohort-specific artifact.
The hsa-miR-130a-3p and hsa-miR-381-3p components of the signature serve as regulatory hubs within the ceRNA network, with multiple lncRNA sponge interactions and downstream mRNA targets. Their dysregulation in high-risk tumors disrupts normal post-transcriptional gene silencing, unleashing proliferative and invasive programs.
BTBD11 and HECW2 are components of ubiquitin ligase complexes involved in protein turnover and signaling pathway regulation. Their altered expression in high-risk tumors may disrupt protein homeostasis in ways that favor tumor cell survival under the metabolic stress conditions typical of the metastatic microenvironment.
RASD1, encoding a Ras-related GTPase, and RFLNB, a cytoskeletal remodeling protein, complete the signature with roles in signal transduction and cell motility. The convergence of these diverse molecular functions within a single ceRNA-based signature reflects the multi-dimensional nature of metastatic competence in ccRCC.
The 11-gene ceRNA signature provides a transcriptomic tool for prognosis prediction in metastatic ccRCC that is grounded in a mechanistically coherent regulatory framework. Its validation in an independent international cohort supports its potential utility as a clinical biomarker panel.
Future studies should explore the signature's performance in patients receiving contemporary ICI-based combination therapies, as the current validation was largely performed in patients treated with older targeted therapy regimens. The regulatory relationships between signature components may also suggest novel combination therapy strategies.
Prospective validation in larger cohorts with standardized treatment protocols, integration with clinical staging information and imaging biomarkers, and exploration of tissue-agnostic liquid biopsy applications (e.g., circulating lncRNA levels) represent important next steps toward clinical implementation of this signature.